RU96105062A - USE OF BENZIDAMINE FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSED BY TNF - Google Patents

USE OF BENZIDAMINE FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSED BY TNF

Info

Publication number
RU96105062A
RU96105062A RU96105062/14A RU96105062A RU96105062A RU 96105062 A RU96105062 A RU 96105062A RU 96105062/14 A RU96105062/14 A RU 96105062/14A RU 96105062 A RU96105062 A RU 96105062A RU 96105062 A RU96105062 A RU 96105062A
Authority
RU
Russia
Prior art keywords
benzidamine
tnf
physiologically acceptable
acid addition
acceptable acid
Prior art date
Application number
RU96105062/14A
Other languages
Russian (ru)
Other versions
RU2160102C2 (en
Inventor
ЧИОЛИ Валерио
Original Assignee
Анджелини Ричерке С.П.А. Сочиета Консортиле
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT93MI001673A external-priority patent/IT1276040B1/en
Application filed by Анджелини Ричерке С.П.А. Сочиета Консортиле filed Critical Анджелини Ричерке С.П.А. Сочиета Консортиле
Publication of RU96105062A publication Critical patent/RU96105062A/en
Application granted granted Critical
Publication of RU2160102C2 publication Critical patent/RU2160102C2/en

Links

Claims (1)

1. Применение бензидамина и его физиологически приемлемых солей присоединения кислоты для получения лекарства для лечения патологических состояний, вызванных ФНО.1. The use of benzidamine and its physiologically acceptable acid addition salts for the manufacture of a medicament for the treatment of pathological conditions caused by TNF. 2. Применение бензидамина и его физиологически приемлемых солей присоединения кислоты по п. 1, отличающееся тем, что патологическое состояние, вызванное ФНО, выбрано из группы, состоящей из септического шока, кахексии, общей дебилитации, которая сопровождает опухолевые (неопластические) заболевания, хронических вирусных и бактериальных инфекций, дегенеративных заболеваний. 2. The use of benzidamine and its physiologically acceptable acid addition salts according to claim 1, characterized in that the pathological condition caused by TNF is selected from the group consisting of septic shock, cachexia, general debilitation, which accompanies tumor (neoplastic) diseases, chronic viral and bacterial infections, degenerative diseases. 3. Применение бензидамина и его физиологически, приемлемых солей присоединения кислоты по п. 2, отличающееся тем, что бактериальной инфекцией является туберкулез,
4. Применение бензидамина и его физиологически приемлемых солей присоединения кислоты по п. 2, отличающееся тем, что вирусной инфекцией является СПИД.3. The use of benzidamine and its physiologically acceptable acid addition salts according to claim 2, characterized in that the bacterial infection is tuberculosis,
4. The use of benzidamine and its physiologically acceptable acid addition salts according to claim 2, characterized in that the viral infection is AIDS. 5. Применение бензидамина и его физиологически приемлемых солей по п. 2, отличающееся тем, что дегенеративными заболеваниями являются множественный склероз или язвенный колит. 5. The use of benzidamine and its physiologically acceptable salts according to claim 2, characterized in that degenerative diseases are multiple sclerosis or ulcerative colitis. 6. Способ лечения патологических состояний, вызванных ФНО, отличающийся тем, что вводят эффективное количество бензидамина или его физиологически приемлемой соли присоединения кислоты пациенту, нуждающемуся в этом. 6. A method of treating pathological conditions caused by TNF, characterized in that an effective amount of benzidamine or a physiologically acceptable acid addition salt thereof is administered to a patient in need thereof. 7. Способ по п. 6, отличающийся тем, что патологическое состояние, вызванное ФНО, выбрано из группы, состоящей из септического шока, кахексии, общей дебилитации, которая сопровождает опухолевые заболевания, хронических вирусных и бактериальных инфекций, дегенеративных заболеваний. 7. The method according to p. 6, characterized in that the pathological condition caused by TNF is selected from the group consisting of septic shock, cachexia, general debilitation, which accompanies tumor diseases, chronic viral and bacterial infections, degenerative diseases. 8. Способ по п. 7, отличающийся тем, что бактериальной инфекцией является туберкулез. 8. The method according to p. 7, characterized in that the bacterial infection is tuberculosis. 9. Способ по п. 7, отличающийся тем, что вирусной инфекцией является СПИД. 9. The method according to p. 7, characterized in that the viral infection is AIDS. 10. Способ по п. 7, отличающийся тем, что дегенеративным заболеванием является множественный склероз или язвенный колит. 10. The method according to p. 7, characterized in that the degenerative disease is multiple sclerosis or ulcerative colitis. 11. Способ по одному из пп. 6 - 10, отличающийся тем, что эффективное количество бензидамина в виде основания бензидамина составляет 0,1 - 10 мг/кг в день. 11. The method according to one of paragraphs. 6 to 10, characterized in that the effective amount of benzidamine in the form of a benzidamine base is 0.1 to 10 mg / kg per day. 12. Способ по одному из пп. 6 - 11, отличающийся тем, что эффективное количество бензидамина в виде основания бензидамина составляет 3 - 10 мг/кг в день. 12. The method according to one of paragraphs. 6 to 11, characterized in that the effective amount of benzidamine in the form of a benzidamine base is 3 to 10 mg / kg per day.
RU96105062/14A 1993-07-27 1994-07-14 Benzidamine application method for treating pathologic states induced by functional metabolism disorders RU2160102C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT93MI001673A IT1276040B1 (en) 1993-07-27 1993-07-27 USE OF BENZIDAMINE IN THE TREATMENT OF PATHOLOGICAL STATES CAUSED BY TNF
ITM193A001673 1993-07-27

Publications (2)

Publication Number Publication Date
RU96105062A true RU96105062A (en) 1998-05-20
RU2160102C2 RU2160102C2 (en) 2000-12-10

Family

ID=11366694

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96105062/14A RU2160102C2 (en) 1993-07-27 1994-07-14 Benzidamine application method for treating pathologic states induced by functional metabolism disorders

Country Status (25)

Country Link
US (1) US6300358B1 (en)
EP (1) EP0711163B1 (en)
JP (1) JP3587851B2 (en)
CN (1) CN1085528C (en)
AT (1) ATE207353T1 (en)
AU (1) AU692458B2 (en)
BG (1) BG62841B1 (en)
CA (1) CA2167926C (en)
CZ (1) CZ285864B6 (en)
DE (1) DE69428797T2 (en)
DK (1) DK0711163T3 (en)
ES (1) ES2163450T3 (en)
HU (1) HU226805B1 (en)
IT (1) IT1276040B1 (en)
LV (1) LV11524B (en)
NO (1) NO308195B1 (en)
NZ (1) NZ269563A (en)
PL (1) PL312741A1 (en)
PT (1) PT711163E (en)
RO (1) RO117149B1 (en)
RU (1) RU2160102C2 (en)
SI (1) SI0711163T1 (en)
SK (1) SK281895B6 (en)
WO (1) WO1995003799A1 (en)
ZA (1) ZA945431B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101199515B (en) * 2007-12-21 2010-12-08 重庆市莱美药物技术有限公司 Hydrochloric acid benzydamine and preparing method thereof
WO2010093588A1 (en) * 2009-02-10 2010-08-19 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
HUE028220T2 (en) * 2009-07-08 2016-12-28 Acraf Use of benzydamine in the treatment of p40-dependent diseases
MD4291C1 (en) * 2013-12-27 2015-02-28 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Medicinal preparation for the treatment of otitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (en) * 1963-08-09
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release

Similar Documents

Publication Publication Date Title
RU93051522A (en) METHOD FOR TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASING THE LEVEL OF THE FACTOR CAUSING NECROSIS OF TUMOR CELLS
JPH04364133A (en) Use of anti-tnf antibody as medicine for treatment of ischemia and its concomitant symptom
RU96115200A (en) 2,4-DISULFOFENYLBUTILNITRON, ITS SALT AND THEIR APPLICATION AS PHARMACEUTICAL SPIN TRAPS
LU92098I2 (en) Adalimumab and its pharmaceutically acceptable derivatives (HUMIRA®)
ATE231519T1 (en) DINUCLEOTIDES FOR USE IN THE TREATMENT OF LUNG DISEASES
RU96105062A (en) USE OF BENZIDAMINE FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSED BY TNF
EP0342587A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
EP0328924A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
RU97104483A (en) SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT
EP0354568A3 (en) Novel catechol derivatives
EP0286825A3 (en) Use of 3'-fluro-3' deoxythymidine for the manufacture of a medicament for the treatment of virus infections
CA2028514A1 (en) Treatment of depression
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
CA2045761A1 (en) Ws7622a mono- or di- sulfate, process for preparation thereof and use thereof
CA2131787A1 (en) Antipruritic
ATE207353T1 (en) USE OF BENZYDAMINE TO TREAT MEDICAL CONDITIONS CAUSED BY TNF
EP0457336B1 (en) Use of mizoribine for the treatment or prevention of multiple sclerosis
CA2037831A1 (en) Methods for the treatment of demyelinating disease, uveitis, or graft-versus-host disease
JP2863821B2 (en) Antiprotozoal agent
US5942224A (en) Therapeutic agent for cat respiratory diseases and method of treatment using the same
PT85076A (en) Method for the treatment of infections disease by administration of tumor necrosis factor-alpha
SU1629062A1 (en) Method for treatment of calves with colibacillosis
SU1034741A1 (en) Tuberculosis treatment method
JP2001131073A5 (en)
RU2002129950A (en) METHOD FOR PREVENTION AND TREATMENT OF BRUCELLOSIS